Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin?

Psychopharmacology

Volumn 114, Issue 4, 1994, Pages 539-550

  Sarter, Martin ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Acetylcholine; Attention; Benzodiazepine receptor; Dopamine; GABA; Schizophrenia; Senile dementia

Indexed keywords

4 AMINOBUTYRIC ACID; 5 ISOPROPOXY 4 METHYL BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; ACETYLCHOLINE; BENZODIAZEPINE RECEPTOR; BENZODIAZEPINE RECEPTOR INVERSE STIMULATING AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; PHYSOSTIGMINE; SARMAZENIL; SCOPOLAMINE;

ATTENTION; BRAIN CORTEX; CHOLINERGIC SYSTEM; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; GABAERGIC SYSTEM; HUMAN; HYPOTHESIS; INFORMATION PROCESSING; NONHUMAN; NUCLEUS ACCUMBENS; PEDUNCULAR ANSA; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SENILE DEMENTIA;

ATTENTION; DEMENTIA; HUMAN; NERVOUS SYSTEM; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028227534     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF02244983     Document Type: Article

References (169)

1. Cell excitation enhances muscarinic cholinergic responses in rat association cortex
2. Coping with attentional disorders as a systemic process in schizophrenic patients
3. The disorder of consciousness in schizophrenia
4. The distinction of positive and negative symptoms. The failure of a two-dimensional model
5. High dose diazepam in schizophrenia
6. Antipsychotic medication effects on neuropsychological functions
7. Memory performance in individuals with primary degenerative dementia: its similarity to diazepam-induced impairments
8. Some behavioral changes in man following anticholinesterase administration
9. Gating and habituation of the startle reflex in schizophrenic patients
10. Schizophrenia: yesterday's concept
11. Modeling dementia: effects of scopolamine on memory and attention
12. Modulation of frontal cortical acetylcholine release by benzodiazepine receptor ligands: age-dependent effects and behavioral correlates
13. FG 7142, a negative modulator at the GABAA/benzodiazepine receptor, increases cortical acetylcholine efflux: interactions with dopamine receptor ligands
14. Nucleus basalis and thalamic control of neocortical activity in the freely moving rat
15. Human information-processing: some effects of methylphenidate, age and scopolamine
16. Effects of scopolamine on human stimulus evaluation
17. Changes in cortical acetylcholine output induced by modulation of the nucleus basalis
18. Acetylcholine released from cerebral cortex in relation to state of activation
19. Cholinergic “blockade” as a model of the cognitive deficits in Alzheimer's disease
20. A theory of dopamine function and its role in cognitive deficits in schizophrenia
21. Evolving conceptions of memory storage, selective attention, and their mutual constraints within the human information-processing system
22. Antianxiety treatments and human memory
23. Benzodiazepines, memory and mood: a review
24. Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood
25. Cholinergic involvement in mental disorders
26. Dopaminergic regulation of cortical acetylcholine release
27. Evidence for a cholinergic mechanism of “learned” changes in the responses of barrel field neurons of the awake and undrugged rat
28. A cancellation test: its reliability in assessing attentional deficits in Alzheimer's disease
29. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease
30. Cholinergic modulation of sensory processes in rat primary somatic sensory cortex
31. Severe anxiety induced by FG 7142, a β-carboline ligand for benzodiazepine receptors
32. Human memory and the cholinergic system: a relationship to aging?
33. Effects of cholinergic agents on human learning and memory
34. Memory decline in the aged: treatment with lecithin and physostigmine
35. Failure of chlordiazepoxide to reproduce the behavioral effects of muscimol administered into the basal forebrain
36. Dissociation between the effects of benzodiazepine receptor agonists on behavioral vigilance and responsivity
37. Human studies on the benzodiazepine receptor antagonist β-carboline ZK 93 426: preliminary observations on psychotropic activity
38. Scopolamine as a pharmacological tool to study memory processes: application of a cognitive enhancer
39. Scopolamine and the control of attention in humans
40. The New York high-risk project: anhedonia, attentional deviance, and psychopathology
41. A review of the neurophysiological effects of lysergic acid diethylamide (LSD) and other psychotomimetic agents
42. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence
43. Directed and divided attention in Alzheimer's disease: impairment in shifting of attention to global and local stimuli
44. Trihexyphenidyl abuse: therapeutic implication for negative symptoms of schizophrenia?
45. Selective attention skills in Alzheimer's disease: performance on graded cancellation tests varying in density and complexity
46. Thalamic radiodensity and cognitive performance in mild and moderate dementia of the Alzheimer's type
47. Neurochemical studies of early onset Alzheimer's disease
48. Selective attention in Alzheimer's disease: CSF correlates of behavioral impairments
49. Elementary neuronal dysfunctions in schizophrenia
50. In what context is latent inhibition relevant for the symptoms of schizophrenia?
51. Effects of flunitrazepam on memory and their reversal by two antagonists
52. Psychiatric sequelae of chronic exposure to organophosphorus insecticides
53. The basis for choice reaction time slowing in Alzheimer's disease
54. Divided attention, as measured by dichotic speech performance, in dementia of the Alzheimer type
55. A longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type
56. The neuropsychology of schizophrenia
57. Increased distractibility in schizophrenic patients
58. The use of semantic knowledge in Alzheimer's disease: evidence for impairments in attention
59. Cognitive abnormalities and schizophrenic symptoms
60. Improved radial maze performance induced by the benzodiazepione receptor antagonist ZK 93 426 in lesioned and alcohol-treated rats
61. Attenuation of muscarinic receptor blockade-induced impairment of spatial delayed alterantion performance by the triazole MDL 26,479
62. Interactions between the effects of basal forebrain lesions and chronic treatment with MDL 26,479 on learning and markers of cholinergic transmission
63. Cognitive functions affected by scopolamine in Alzheimer's disease and normal aging
64. Short-term memory impairments in Alzheimer-type dementia: evidence for separable impairments of articulatory rehearsal and long-term memory
65. Adverse effects of anticholinergic medication in positive schizophrenic symptoms: theoretical and practical considerations
66. Controlled and automatic information processing in senile dementia: a review
67. Cholinergic depletion prevents expansion of topographic maps in somatosensory cortex
68. Basic phenomena underlying novel use of cholinergic agents, anticholinesterases and precursors in neurological including peripheral and psychiatric disease
69. Significance of the positive-negative distinction in schizophrenia
70. Diazepam treatment of early symptoms of schizophrenic relapse
71. Converging models of cognitive deficit in schizophrenia
72. Benzodiazepines and vigilance performance: a review
73. The mechanism of excitation by acetylcholine in the cerebral cortex
74. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease
75. Ibotenic acid lesions of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat
76. The use of benzodiazepines in schizophrenia
77. Anxiogenic drugs beta-CCE and FG 7142 increase extracellular dopamine levels in the nucleus accumbens
78. A valid vigilance test for rats: effects of age, time on test, signal intensity, and psychotropic drugs
79. Disorders of attention and perception in early schizophrenia
80. Amnesic syndrome in schizophrenia
81. Large-scale neurocognitive networks and distributed processing for attention, language, and memory
82. Nucleus basalis stimulation facilitates thalamocortical synaptic transmission in the rat auditory cortex
83. Cholinergic modulation of responses to single tones produces tone-specific receptive field alterations in cat auditory cortex
84. Acetylcholine modifies neuronal acoustic rate-level functions in guinea pig auditory cortex by an action at muscarinic receptors
85. Ventral pallidum projections to mediodoral nucleus of the thalamus: an anatomical and electrophysiological investigation in the rat
86. Characterization of dopamine release in the rat medial prefrontal cortex as assessed by in vivo microdialysis: comparison to the striatum
87. Toward modeling age-related changes of attentional abilities in rats: simple and choice reaction time tasks and vigilance
88. Age-dependent modulation of in vivo cortical acetylcholine release by benzodiazepine receptor ligands
89. Bidirectional modulation of stimulated cortical acetylcholine release by benzodiazepine receptor ligands
90. Modulation of cortical ACh efflux by GABA/benzodiazepine receptor ligands: effects of repeated testing and interactions with dopamine receptors
91. Modulation of stimulated cortical acetylcholine efflux by benzodiazepine receptor ligands is mediated in the basal forebrain
92. The nature of memory impairment in Alzheimertype dementia
93. The positive:negative dichotomy in schizophrenia
94. No response to high-dose muscarinic agonist therapy in Alzheimer's disease
95. Disruptive effects of muscimol infused into the basal forebrain on conditional discrimination and visual attention: differential interactions with cholinergic mechanisms
96. Cholinergic enhancement of direction selectivity in the visual cortex of the cat
97. Signal detection indices in schizophrenics on a visual, auditory, and bimodal continuous performance test
98. Physostigmine, a highly potent antidote for acute experimental diazepam intoxication
99. Generalized cognitive slowing and severity of dementia in Alzheimer's disease: implications for the interpretation of response-time data
100. Cognitive slowing in Alzheimer's disease and geriatric depression
101. Diazepam in high doses is effective in schizophrenia
102. Attentional requirements of learning: evidence from performance measures
103. Information processing and attentional functioning in the developmental course of schizophrenia
104. Attention and driving skills in aging and Alzheimer's disease
105. Visuospatial attention in dementia of the Alzheimer type
106. The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance
107. Effects of GABA compounds injected into the subpallidal regions of rat brain on nucleus accumbens evoked hyperactivity
108. Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia
109. Convergent cholinergic activities in aging and Alzheimer's disease
110. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia
111. Basal forebrain and frontal cortex neuron responses during visual discrimination in the rat
112. A role for acetylcholine in conditioning-related responses of rat frontal cortex neurons: microiontophoretic evidence
113. Adverse effects of single therapeutic doses of diazepam on performance in normal geriatric subjects: relationship to plasma concentrations
114. The attention system of the human brain
115. Effects of lorazepam on memory, attention and sedation in man
116. Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine
117. Long-term enhancement of evoked potentials in cat somatosensory cortex produced by coactivation of the basal forebrain and cutaneous receptors
118. Functional implications of tonic and phasic activity changes in nucleus basalis neurons
119. Psychopharmacological and neurobiological aspects of the energetics of information processing
120. Comparative effects of ibotenic acid- and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes
121. The effects of diisopropylfluorophosphate in schizophrenia and manic-depressive psychosis
122. A comparison of the effects of scopolamine and diazepam on working memory
123. Cholinergic drugs and human cognitive performance
124. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB
125. Sparing of attentional relative to mnemonic function in a subgroup of patients with dementia of the Alzheimer type
126. Dopamine-GABA-cholinergic interactions and negative schizophrenic symptomatology
127. Activating the damaged basal forebrain cholinergic system: Tonic stimulation versus signal amplification
128. Cholinergic controversies
129. Cognition enhancement based on GABA-cholinergic interactions
130. Behavioral screening for cognition enhancers: from indiscriminate to valid testing. Part I
131. Behavioral screening for cognition enhancers: from indiscriminate to valid testing. Part II
132. Effects of cholinergic depletion on neuron activities in the cat visual cortex
133. Visual controlled information processing resources and formal thought disorder in schizophrenia and mania
134. Cholinergic modulation of the functional organization of the cat visual cortex
135. The cholinergic modulation of cortical function
136. Cognitive alterations as markers of vulnerability to schizophrenia
137. Influence of substantia innominata neuronal activity on neocortex neuronal reactions during conditioned reflex
138. Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls
139. Substantia innominata: critical link in the behavioral expression of mesolimbic dopamine stimulation in the rat
140. Lesions of the dorsomedial nucleus of the thalamus, medial prefrontal cortex and pedunculopontine nucleus: effects on locomotor activity mediated by nucleus accumbens-ventral pallidal circuitry
141. Cholinergic hyperactivity and negative schizophrenic symptoms
142. Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms
143. Cholinergic hyperactivity and negative symptoms: behavioral effects of physostigmine in normal controls
144. Cognitive effects of L-deprenyl in Alzheimer's disease
145. Anxiogenic properties of beta-CCE and FG 7142: a review of promises and pitfalls
146. Electrophysiological studies of acetylcholine and the role of the basal forebrain in the somatosensory cortex of the cat II. Cortical neurons excited by somatic stimuli
147. Comparison of radial maze performance of rats after ibotenate and quisqualate lesions of the basal forebrain cholinergic projection system: effects of pharmacological challenge and changes in training regime
148. Input dysfunction in schizophrenia
149. Hippocampal function and schizophrenia
150. Microbehavioural analysis of the choice reaction time response in senile dementia
151. Psychological aspects of information-processing and stress
152. Neurochemical basis of behaviour
153. Cholinergic systems and information processing capacity
154. Acetylcholine and attentional disorders
155. Implications of normal brain development for the pathogenesis of schizophrenia
156. Measurement and interpretation of changes in memory in response to drug treatments
157. Characterizing anticholinergic abuse in community mental health
158. An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg s.c.
159. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal
160. Diazepam-induced amnesia: a neuropharmacological model of an “organic amnesic syndrome”
161. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients
162. Cholinergic systems in mammalian brain and spinal cord
163. Ventral pallidal responses to dopamine receptor stimulation in the nucleus accumbens
164. Afferents to basal forebrain cholinergic projection neurons: an update